Search
EHA Pediatric Hemato-Oncology Course 2024
Join us in Sorrento to develop your problem-solving skills and exchange ideas in a friendly and supportive environment. DatesApril 10–13, 2024. LocationGrand Hotel Riviera, Sorrento, Italy.
Read moreEHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy
Dates: November 23-25, 2017
Location: Amsterdam, The Netherlands
Chair: WE Fibbe, F Dazzi
Organized by:
EHA and the EHA Scientific Working Group on Mesenchymal Stromal Cells
The SWG Meeting “Shaping the future of MSC therapy” brought together basic science, as well as translational and clinical research.…
GoCART Coalition - Call for research proposals within Work Package 6: Scientific Excellence
Dear GoCART community,
With more than 1500 CAR-T infusions registered in the EBMT registry, EHA and EBMT are proud to announce a series of scientific calls within Work Package 6: Scientific Excellence of the GoCART coalition.
EHA Lymphoma Group
The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.
Read moreThe European Parliament adopts the Regulation on Substances of Human Origins (SoHO)
On April 24, the European Parliament gave its final endorsement to the regulation on Substances of Human Origin (SoHO).
Read moreMessage from the EHA President
As the year closes, is with great pleasure that I reflect on 2021, six months into my Presidency of the European Hematology Association (EHA). It is also time to look forward to the new year.
Read moreGreat new opportunity for the YoungEHA community!
Great new opportunity for the YoungEHA community!
by Dr Nuno Borges, YoungEHA committee
The European Medicines Agency (EMA) has launched the 'Collaborating Expert Programme' - an initiative which aims to increase co-operation between European countries to improve research into medicinal products.…
Recommendation for hematologists in COVID-19 crisis
Recommendations for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in patients with active cancer. It should be taken seriously and managed rigorously without jeopardizing the curative chance of individual cancer patients.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- »